title: The Mitroflow pericardial bioprosthesis. Comparison of early clinical performance in aortic and mitral positions.
abstract: Between 1983 and 1987 the Mitroflow pericardial prosthesis was implanted in 354 patients, ranging in age from 14 to 94 years (mean 60.1 years). The early mortality was 5.7% and the late mortality 2.9% per patient-year. The total cumulative follow-up was 853 years (mean 2.4 years). Patient survival at 4 years for aortic valve replacement (AVR) was 81.5% and for mitral valve replacement (MVR) 74.8%. The overall rate of valve-related complications was 4.8% per patient-year (41 complications): thromboembolism, 15; hemorrhage related to antithromboembolic therapy, 1; prosthetic valve endocarditis, 15; nonstructural dysfunction, 3; and structural valve deterioration, 7. At 4 years the freedom from thromboembolism was 91.5% +/- 2.7% for AVR and 91.1% +/- 4.0% for MVR, from prosthetic valve endocarditis 93.5% +/- 2.3% for AVR and 94.0% +/- 2.9% for MVR, from structural valve deterioration 97.3% +/- 2.1% for AVR and 92.6% +/- 3.2% for MVR, from valve-related mortality 96.9% +/- 1.4% for AVR and 97.5% +/- 1.8% for MVR, and from reoperation 93.5% +/- 2.8% for AVR and 83.1% +/- 5.1% for MVR. The freedom from the composite of all valve-related complications at 4 years was 81.1% +/- 4.2% for AVR and 75.3% +/- 2.8% for MVR. The Mitroflow valve has provided satisfactory clinical performance at the 4-year evaluation. Structural valve deterioration is greater in the mitral position than in the aortic position. Long-term evaluation of the Mitroflow valve is necessary to determine the impact of structural valve deterioration on its clinical performance.
authors.affiliation: Department of Surgery, University of British Columbia, Vancouver.
authors.forename: W R
authors.initials: WR
authors.lastname: Jamieson
authors.forename: L C
authors.initials: LC
authors.lastname: Pelletier
authors.forename: A N
authors.initials: AN
authors.lastname: Gerein
authors.forename: J
authors.initials: J
authors.lastname: Pomar
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001021:Aortic Valve / Q000601:surgery*; D001705:Bioprosthesis; D005500:Follow-Up Studies; D006350:Heart Valve Prosthesis / Q000009:adverse effects / Q000401:mortality; D006801:Humans; D008875:Middle Aged; D008943:Mitral Valve / Q000601:surgery*; D012086:Reoperation